Source library · updated June 5, 2026

Authoritative sources behind the tirzepatide price guide

This page lists the regulatory, manufacturer, clinical, pharmacy-verification, and advertising-disclosure sources used to check pricing claims and safety language. Provider prices still change frequently; verify directly before making a decision.

FDA regulatory statusLilly brand-price contextNEJM/PubMed clinical evidenceFTC/NABP trust checks

Primary references

Sources we prioritize

We prioritize primary or official sources when available. Competitor and provider pricing pages are used for commercial price claims, but regulatory and medical safety statements are checked against independent authorities.

Regulatory sourceFDA — GLP-1 compounding policy and shortage statusFDA policy context on GLP-1 compounding, shortage resolution, and enforcement expectations. Regulatory sourceFDA — Compounded drugs are not FDA-approvedExplains how compounded drugs differ from FDA-approved products. Manufacturer pricing sourceEli Lilly — Zepbound pricing informationCurrent brand-name pricing context for Zepbound with and without insurance. Manufacturer sourceLillyDirect — Zepbound terms and vial/KwikPen cash pricesSelf-pay pricing context for Zepbound vial/KwikPen options and terms. Clinical evidenceNew England Journal of Medicine — SURMOUNT-1Pivotal 72-week obesity trial for tirzepatide efficacy and safety outcomes. Clinical evidence indexPubMed — Tirzepatide once weekly for obesityPubMed record for SURMOUNT-1. Trial registryClinicalTrials.gov — SURMOUNT-1 NCT04184622Trial registry record for tirzepatide obesity study. Advertising complianceFTC — Endorsement Guides and material connectionsDisclosure framework for commercial relationships and endorsements. Pharmacy trust signalNABP — Healthcare merchant and pharmacy accreditation resourcesBackground on pharmacy and healthcare accreditation signals users can verify.

How to use these sources

Use FDA pages to understand whether compounded tirzepatide is FDA-approved and how shortage policy affects compounding. Use Lilly pages to compare brand-name cash pricing. Use NEJM, PubMed, and ClinicalTrials.gov for clinical evidence. Use FTC and NABP resources to evaluate disclosure quality, pharmacy verification, and trust signals.

This site is educational and commercial editorial content, not medical advice. A licensed clinician must determine whether any medication is appropriate for an individual patient.

Additional follow-up answer sources

Semaglutide vs tirzepatide efficacy follow-up: NEJM SURMOUNT-1 and 2025 head-to-head trial summaries.
Compounded GLP-1 safety follow-up: FDA warnings on unapproved GLP-1 drugs and compounded dosing errors.
LegitScript/FDA follow-up: LegitScript healthcare certification pages and FDA compounding guidance.
Competitor comparison follow-up: official Hims, Found, and Lemonaid public pricing/program pages where available.